Lung cancer maintenance combo trial halted early
NCT ID NCT03559049
First seen Feb 17, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study looked at whether adding the drug rucaparib to the immunotherapy pembrolizumab could help keep stage IV non-small cell lung cancer from growing after initial treatment. It involved 25 adults whose cancer had not worsened after standard chemotherapy plus pembrolizumab. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.